New cell therapy takes on advanced stomach cancer
NCT ID NCT07406984
First seen Feb 23, 2026 · Last updated Apr 26, 2026 · Updated 9 times
Summary
This early-phase study tests a new treatment called IM96 CAR-T cells for people with advanced stomach or esophageal junction cancer that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to better target and attack cancer cells. The main goal is to check safety and side effects, while also seeing if it can shrink tumors or slow disease progression. Only 18 adults will take part in this single-center trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF GASTRIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.